Nasdaq Stockholm

Hansa Biopharma AB

ISIN SE0002148817Filings at the FI

At a glance

Most recent filing on September 28, 2026 — an open-market purchase by Renée Aguiar Lucander on Sep 25, 2026.

We hold 61 visible filings, going back to June 14, 2018.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

What is a MAR filing?

5 of 61 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings at this company, out of 61. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are the price history with every buy marked, the price change beside each line, and any moments with several buyers or buying streaks. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Renée Aguiar Lucander Chief executive officer
1,503,060 SEKOpen-market buy
TradedSep 25, 2026FiledSep 28, 2026
Devin Holden Closely associated: Board member
1,425,598 SEKOpen-market sale
TradedSep 10, 2026FiledSep 14, 2026
Devin Holden Closely associated: Board member
2,805,659 SEKOpen-market sale
TradedAug 12, 2026FiledAug 18, 2026
Devin Holden Closely associated: Board member
3,327,387 SEKOpen-market sale
TradedAug 14, 2026FiledAug 18, 2026
Devin Holden Closely associated: Board member
4,954,977 SEKOpen-market sale
TradedAug 13, 2026FiledAug 18, 2026

Short positions

All short positions

Net short positions of 0.5% or more in Hansa Biopharma AB that are open today, as the regulator publishes them. Together they come to 1.60% of the shares. Positions below 0.5% are not published, so the real total can be higher.

2 open positions, together 1.60%. The holders and their history are part of the subscription.

Källa: Finansinspektionen, October 31, 2026.